sunvozertinib

SHANGHAI, China, July 14, 2026 Dizal has entered into a landmark global exclusive license agreement with AstraZeneca for Zegfrovy...

SHANGHAI, China, May 27, 2026 Dizal, a biopharmaceutical company focused on developing targeted oncology therapies, has announced that China’s...

Shanghai, China | March 21, 2026 Dizal has announced positive topline results from its multinational Phase 3 WU-KONG28 clinical...